title: Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
authors.affiliation: Caitlin Mullins is a pharmacy resident at Froedtert & Medical College of Wisconsin, Milwaukee, W.I. Whitney Gibson is a pharmacy student at Wingate University Wingate, N.C. Olga M. Klibanov is a professor of pharmacy at Wingate University, Wingate, N.C.
authors.forename: Caitlin
authors.initials: C
authors.lastname: Mullins
authors.forename: Whitney
authors.initials: W
authors.lastname: Gibson
authors.forename: Olga M
authors.initials: OM
authors.lastname: Klibanov
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000075202:Contraindications; D004347:Drug Interactions; D005449:Fluorenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy* / Q000451:nursing; D006801:Humans; D009722:Nurse Practitioners; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D000069474:Sofosbuvir; D014542:Uridine Monophosphate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; C000595958:ledipasvir, sofosbuvir drug combination; D014542:Uridine Monophosphate; D000069474:Sofosbuvir